Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Osiris nets $35.8mm with IPO

Executive Summary

Osiris Therapeutics (stem cell company developing treatments for inflammatory, orthopedic, and cardiovascular conditions) has netted $35.8mm with its initial public offering of 3.5mm common shares priced at $11 each. When the company first filed for the IPO back in May, it had hoped to bring in up to $80mm.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies